Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis

A legfontosabb adatok

Ki végzi
Methodist Health System
Hol
Dallas (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
42 fő vett részt
Kezdés
2020. nov. 5.
Befejezés
2025. júl. 14.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Omadacycline
A regiszteradat frissítve
2026. március 27.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Female and male subjects will be eligible for inclusion if hospitalized, 18 years or older, diagnosed with type 1 or 2 diabetes, and have DFI with the additional clinical criteria as specified below:; Acute infection or worsening without systemic antimicrobials within the previous 14 days; At least one full or partial thickness-infected ulcer at or below the ankle AND; Purulent drainage OR; Two of the following:; Erythema; Local edema; Fluctuance; Induration; Increased local warmth; Fever; No systemic antimicrobials with current hospital admission for more than 48 hours prior to enrollment
  • Inclusion will be based on; Empiric coverage based on organisms suspected to be caused by susceptible bacteria, if no culture identifies a specific organism; or; Confirmed susceptibility to omadacycline against any organism identified. Any subject in which a pathogen resistant to omadacycline is identified will be excluded from the study and antibiotics will be changed based on physician discretion; First episodes of AOM at qualifying site of infection will be eligible for inclusion with any of the following criteria confirming the diagnosis:; Imaging (X-ray or MRI) confirmation of acute osteomyelitis; Pathology (bone biopsy/culture); Not currently enrolled in any other clinical trial; Provides informed consent; Likely to be compliant with all study-related procedures and visits

Ki nem vehet részt

  • Chronic osteomyelitis; Osteomyelitis of the same site previously treated with antibiotics; Documented presence of osteomyelitis more than 2 weeks prior to index admission; Necrotic or dead bone identified by pathology; Unclear chronicity of infection (if unable to determine acute osteomyelitis)
  • Contraindication or hypersensitivity to omadacycline/tetracyclines
  • Age less than 18 years
  • Pregnant women
  • Has any gangrenous ulcers or necrotizing fasciitis
  • Has a pathogen known to be resistant to omadacycline
  • Administration of additional systemic antibiotics in combination with omadacycline, not including topical routes or oral vancomycin/fidaxomicin given their local activity within the GI tract
  • Unwilling or unable to participate in study-related procedures or visits

Helyszínek itt: Egyesült Államok

  • Methodist Charlton Medical CenterDallas, Egyesült Államok
  • Methodist Dallas Medical CenterDallas, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This will be a prospective, open-label, two-center study to assess the safety of omadacycline use in the treatment of hospitalized subjects with moderate to severe DFI with or without Acute osteomyelitis (AOM) who are at a high risk for development of CDI, AKI, and/or resistant pathogens compared to retrospective controls. Prospective enrollment will be continued until the sample size is achieved up to one year from start date (October 2020).

A teljes eredeti leírásKevesebb

Secondary to slower than anticipated enrollment due to the COVID-19 pandemic and initial exclusion of AOM, following protocol amendment, patient enrollment will be continued until the sample size is achieved up to 18 months from amendment approval (anticipate April 2022 - October 2023). A historical matched case cohort (standard of care) at the two hospitals based on ICD10 codes associated with DFI [E11.(621, 622), E10.(621, 622); L97.(509, 521, 522, 523, 524, 529)], including subjects with AOM [M86.(08-09, 10, 16-19, 8X0, 8X7-8X9, 9) will be utilized for comparison.

A vizsgálat 2 csoportja

  • Retrospective Cohort

    A historical matched case cohort

  • Prospective Cohort

    Subjects will be screened daily via review of the EMR reports of inpatient admissions. Those receiving antibiotics with a notated source of skin/soft tissue infection or OM will be further reviewed to determine if the source of infection is a DFI with or without suspected or confirmed Acute osteomyelitis.

    Kezelés: Omadacycline

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Publikációk
A regiszteradat frissítve
2026. március 27.